Funding & VC

Remedy Robotics Raises $62M for AI Cardiovascular Trial Push

Remedy Robotics raised $62 million to move its AI cardiovascular robot N1 toward a pivotal UC trial and FDA review, but the system remains unavailable for clinical use.

By Olivia Hart

4 min read

Remedy Robotics Raises $62M Series B to Advance AI Cardiovascular Care
Remedy Robotics Raises $62M Series B to Advance AI Cardiovascular CareAI-generated

By Olivia Hart

What does the $62 million financing cover?

Remedy Robotics said on November 16, 2026 that it raised $62 million in Series B financing to advance N1, its AI-enabled robotic platform for cardiovascular procedures.

The company said the capital will fund a planned pivotal clinical trial with the University of California, progress toward FDA approval for neurovascular intervention, and prototype N1 deployments across its clinical-partner network. Remedy added that it will continue developing the system’s AI and autonomous functions.

N1 remains under development and is not available for sale or clinical use in any jurisdiction.

Funding buys development time, not market clearance.

Who backed the round, and why does UC matter?

DCVC led the Series B. New investors include UC Investments, the University of California’s investment office, Skip Capital and Australian pension fund Hostplus.

Existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures increased their backing. Remedy said it has worked with UC clinical experts since 2021 and plans to hold the pivotal trials across the university’s network.

CEO and co-founder Dr. David Bell said: “Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals.”

The announcement disclosed no trial-enrollment target, efficacy endpoint or FDA submission date. Those omissions leave the clinical timetable and commercial payoff uncertain.

UC offers a trial network, not evidence that N1 works at scale.

How is N1 designed to work?

Remedy says N1 is designed to complete entire endovascular procedures robotically. It is designed to operate on site, remotely or autonomously across neurovascular, coronary and peripheral vascular care.

Its machine-learning software analyzes preoperative imaging, simulates procedures in advance, and registers three-dimensional images with two-dimensional procedural images in real time. The registration aligns both views during an intervention.

The technical package combines AI-assisted control for off-the-shelf devices with proprietary 360-degree steerable catheters and automated imaging segmentation. No sales or clinical availability accompanies those claims.

Supervised autonomy uses real-time understanding of tool and anatomy positioning. The remote package includes connectivity management, audio and video without third-party integrations. Remedy says the platform is designed for more than 30 cardiovascular conditions.

N1’s technical scope is broad, but the disclosed clinical evidence remains early.

What did the remote Toronto procedures show?

Remedy describes October 2025 procedures as the world’s first fully remote neurointerventional procedures. Dr. Vitor Mendes Pereira and his team operated entirely robotically from St. Joseph’s Health Centre while patients were at St. Michael’s Hospital across Toronto.

No bedside interventionist was required, according to Remedy. The company reports working with more than 100 hospitals worldwide, but it did not disclose how many sites use N1 or how many patients have received it.

Toronto demonstrates remote operation, not safe routine use.

Which partners will test and deploy N1?

Prototype deployments will run through clinical partners, Remedy said, including SVIN Mission Thrombectomy. SVIN selected Remedy as its exclusive robotics partner for N1 testing, development and global rollout.

The Australian Stroke Alliance, which represents 40 health bodies, will work with Remedy through clinical trials, regulatory approval and a planned nationwide rollout. The partnership reaches further than a single hospital, although the announcement gave no approval timetable or rollout budget.

Partner breadth could widen testing, but deployment remains conditional.

How large is the clinical problem?

The World Health Organization estimates cardiovascular diseases caused 19.8 million deaths in 2022, about 32% of all deaths worldwide. Heart attack and stroke caused 85% of those deaths, making the burden roughly one in three global deaths.

A World Stroke Organization–Lancet Neurology Commission estimated stroke’s annual direct and indirect global costs at more than $891 billion. Its 2017 assessment put healthcare expenses as high as $315 billion and lost income at $576 billion.

Those figures combine treatment and rehabilitation with lost income. They establish the economic scale of stroke, not the market size for robotic intervention.

The disease burden is vast, but it does not size the robot market.

What must happen before N1 reaches patients?

The Series B ties Remedy’s progress to clinical milestones rather than immediate commercial availability. Hospital and stroke partnerships offer routes for broader testing, but the remote procedures need pivotal-trial evidence and FDA progress before N1 can enter routine clinical use.

The next proof points are the planned UC pivotal trial, FDA progress and planned partner deployments. Until those results arrive, N1 remains investigational and unavailable for sale or clinical use in any jurisdiction.

Clinical evidence is the next gating factor.

Source: unite.ai

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,205 articles

Related articles

« Previous articleNext article »